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ABSTRACT: Up to 99% of systemically administered
nanoparticles are cleared through the liver. Within the
liver, most nanoparticles are thought to be sequestered by
macrophages (Kupﬀer cells), although signiﬁcant nano-
particle interactions with other hepatic cells have also been
observed. To achieve eﬀective cell-speciﬁc targeting of
drugs through nanoparticle encapsulation, improved mech-
anistic understanding of nanoparticle−liver interactions is
required. Here, we show the caudal vein of the embryonic
zebraﬁsh (Danio rerio) can be used as a model for assessing
nanoparticle interactions with mammalian liver sinusoidal
(or scavenger) endothelial cells (SECs) and macrophages.
We observe that anionic nanoparticles are primarily taken up by SECs and identify an essential requirement for the
scavenger receptor, stabilin-2 (stab2) in this process. Importantly, nanoparticle−SEC interactions can be blocked by
dextran sulfate, a competitive inhibitor of stab2 and other scavenger receptors. Finally, we exploit nanoparticle−SEC
interactions to demonstrate targeted intracellular drug delivery resulting in the selective deletion of a single blood vessel in
the zebraﬁsh embryo. Together, we propose stab2 inhibition or targeting as a general approach for modifying
nanoparticle−liver interactions of a wide range of nanomedicines.
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Cell-type speciﬁc targeting is a common goal innanoparticle drug delivery. However, the inability toeﬃciently target subpopulations of cells, beyond the
macrophages and monocytes of the mononuclear phagocyte
system (MPS), has stymied progress of these technologies into
clinical use.1−4 Up to 99% of systemically administered
nanoparticles, of all shapes, sizes, and chemical compositions
are cleared through the liver.5 While it is generally accepted that
nanoparticles are taken up by liver-resident macrophages
(Kupﬀer cells (KCs)),6 the principal cell type of the MPS in
the liver, signiﬁcant nanoparticle interactions with other hepatic
cells, including liver sinusoidal endothelial cells (LSECs),
hepatocytes, and hepatic B-cells, have also been observed.7−10
In these instances however, the cell-speciﬁc mechanisms
underpinning these interactions have not been elucidated. A
detailed understanding of exactly where and how nanoparticles
are sequestered and cleared within the liver is crucial for the
eﬀective optimization of nanoparticle-mediated drug delivery.
The principle function of the liver is to maintain homeostasis.
This includes the removal (“scavenging”) of macromolecular
and colloidal waste and pathogens from the blood. Within the
liver, scavenging function is primarily associated with the
hepatic sinusoids,11 specialized blood vessels connecting the
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Figure 1. A zebraﬁsh model for liposome biodistribution. (a) Schematic of liposome injection and quantiﬁcation in zebraﬁsh. Fluorescently
labeled liposomes (1 mM total lipids containing 1 mol % Rhod-PE) were injected into the duct of Cuvier at 54 hpf. Confocal microscopy is
performed in a deﬁned region (boxed) caudal to the yolk extension at 1, 8, 24, and 48 h after injection. (b) Whole-embryo view of liposome
distribution in kdrl:GFP transgenic embryos, 1 hpi with three diﬀerent liposome formulations (AmBisome, EndoTAG-1, and Myocet). (c)
High-resolution imaging allows quantiﬁcation of liposomes in circulation (measured in the lumen of the dorsal aorta (white box)) and
liposome association with diﬀerent blood vessel types (see Supporting Information). CHT-EC: caudal hematopoietic tissue endothelial cells,
DLAV: dorsal longitudinal anastomotic vessel. ISV: intersegmental vessel. (d) Tissue level view of liposome distribution in kdrl:gfp transgenic
embryos, 1 h and 8 h after injection with three diﬀerent liposome formulations and a single confocal section through the dorsal aorta (DA) at
1 h after injection. (e) Quantiﬁcation of liposome levels in circulation based on mean rhodamine ﬂuorescence intensity in the lumen of the
dorsal aorta at 1, 8, 24, and 48 h after injection (error bars: standard deviation.) n = 6 individually injected embryos per formulation per time
point (in two experiments). (f) Quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells based on rhodamine
ﬂuorescence intensity associated with caudal vein (CV) vs DA at 8 h after injection. (g) Quantiﬁcation of extravascular liposome levels based
on rhodamine ﬂuorescence intensity outside of the vasculature between the DLAV and DA at 8 h after injection. (h) Quantiﬁcation of
liposome levels associated with the vessel wall based on rhodamine ﬂuorescence intensity associated with all endothelial cells relative to
ACS Nano Article
DOI: 10.1021/acsnano.7b06995
ACS Nano 2018, 12, 2138−2150
2139
hepatic artery and portal vein (incoming blood ﬂow) with the
central vein (outgoing blood ﬂow). In these vessels, scavenging
function is facilitated by a >10-fold decrease in blood ﬂow
velocity.12 Hepatic sinusoids are primarily composed of LSECs
(∼70%) and KCs (∼20%).13 Together these cells comprise the
hepatic reticuloendothelial system (RES), a term originally
proposed in the early 20th century by Aschoﬀ14 to include
specialized cells that accumulated vital stains. Since then, the
term RES has been largely superseded by the MPS, which in
the liver sinusoid includes KCs but not LSECs.
Cells with a scavenging function similar to mammalian
LSECs have been identiﬁed in all vertebrates examined.
However, in teleost ﬁsh, sharks, and lampreys these cells have
not been found in the liver, but are identiﬁed in various other
organs.15 Collectively, these cells are known as scavenger
endothelial cells (SECs), a specialized endothelial cell type
functionally deﬁned as the major clearance site of endogenous
macromolecules such as oxidized low-density lipoprotein
(oxLDL) and hyaluronic acid (HA) from the blood.11
Mammalian LSECs have also been implicated in clearance of
blood-borne viruses from circulation16−18 and are important
cell-types of both the innate and adaptive immune system.19,20
In LSECs, clearance function is mediated through a relatively
small number of pattern-recognition endocytosis receptors.11
Given the wide variety of macromolecules, colloids, and
pathogens sequestered by LSECs, these receptors are clearly
promiscuous with respect to potential binding partners.
However, what general physicochemical properties direct
materials to LSECs, to what extent are individual endocytosis
receptors involved, and the signiﬁcance of these interactions in
the clearance of nanoparticles from circulation are not clearly
deﬁned.
Here, we show a speciﬁc part of the zebraﬁsh embryonic
vasculature displays functional homology to the mammalian
liver sinusoid and includes macrophages/monocytes and
functional SECs. Using this model, we are able to study
which general properties of nanoparticles result in their uptake
by each of these cell types after intravenous injection. For
SECs, we reveal an important molecular mechanism required
for nanoparticle clearance, involving the transmembrane
receptor stabilin-2, which can be both inhibited and exploited
to guide cell-speciﬁc nanoparticle-mediated drug delivery.
RESULTS AND DISCUSSION
A Zebraﬁsh Model for Liposome Biodistribution. Of
the myriad nanoparticles reported as potential drug delivery
vectors, liposomes are the most widely investigated and the
major class of nanoparticles approved for clinical use.21,22 So
far, the ability to predict the fate of liposomes following
intravenous injection based on lipid composition alone has
been limited. Furthermore, the opacity of mammalian models
precludes comprehensive assessment of the dynamic behavior
of liposomes in vivo. Recent studies have shown that the small
and transparent zebraﬁsh embryo allows for the direct
observation of circulating nanoparticles, including liposomes,
and their interactions with cells.23−26 These studies show key
aspects of nanoparticle behavior, including uptake by the MPS,
are conserved between zebraﬁsh and mammals. We therefore
selected this model to identify the inﬂuence of lipid
composition on liposome biodistribution and the mechanisms
of liposome uptake by cells.
Three liposome formulations, either approved for clinical use
or under development (Myocet, EndoTAG-1, and AmBi-
some),27−29 were initially selected for intravenous injection into
zebraﬁsh embryos. These formulations were speciﬁcally chosen
to assess the inﬂuence of contrasting nanoparticle surface
charge. Myocet is a neutral liposomal-doxorubicin formulation
showing extravasation in tumors.27 EndoTAG-1 is a positively
charged liposomal-paclitaxel formulation targeting actively
growing tumor blood vessels.28 AmBisome is a negatively
charged liposomal-amphotericin B formulation used to treat
severe fungal infections.29 Fluorescently labeled liposomes
(∼100 nm in diameter and without encapsulated drugs) based
on the lipid composition of these formulations (Table S1) were
injected intravenously into the duct of Cuvier of zebraﬁsh
embryos at 54 h post-fertilization (hpf), a stage at which most
organ systems are established. Injected embryos were imaged
using confocal microscopy at 1, 8, 24, and 48 h post-injection
(hpi) (Figure 1a), and confocal micrographs were generated for
the entire embryo (whole organism level) as well as from a
region caudal to the cloaca (tissue level) (Figure 1b,d and
Figure S1). We developed a quantiﬁcation method to compare
levels of circulating liposomes, extravasation, and accumulation
in diﬀerent blood vessel types between formulations (Figure
1c,e−h and Figure S2).
At 1 hpi, on a whole organism level, all three liposome
formulations were found associated with the blood vasculature
and over time, the ﬂuorescence associated with freely
circulating liposomes within the lumen of the dorsal aorta,
decayed exponentially (Figure 1b,e). At the tissue level
however, clear diﬀerences in liposome biodistribution were
observed (Figure 1d). Consistent with their behavior in
mammals, neutral Myocet liposomes were mostly seen
circulating within the blood vessel lumen. At 1 hpi, liposome
translocation through the vessel wall (extravasation) was
already evident, and between 1 and 8 hpi, co-localization with
plasma-exposed macrophages was observed (Figure 1d,g,
Figure S3). Increasing the size of Myocet liposomes resulted
in enhanced uptake by macrophages, whereas surface
PEGylationa strategy widely employed to limit nanoparticle
clearance in vivo30eﬀectively inhibited phagocytotic uptake as
described previously (Figure S3).23,26
For EndoTAG-1 and AmBisome, a large fraction of the
injected dose was removed from circulation by 1 hpi and 8 hpi
respectively, and these formulations were found associated with
the vessel wall (Figure 1e,h). Strikingly however, anionic
Figure 1. continued
rhodamine ﬂuorescence intensity in circulation at 1h after injection. (f−h) Bar height represents median values, dots represent individual data
points, brackets indicate signiﬁcantly diﬀerent values (*: p < 0.05, **: p < 0.01, ***: p < 0.001) based on Kruskal−Wallis and Dunn’s tests
with Bonferroni correction for multiple testing. n = 12 individually injected embryos per group (in 2 experiments). (i) Whole-embryo view of
liposome distribution in kdrl:GFP transgenic embryos, 1 h after injection with DOPG and DSPC liposomes. Liposome accumulation for both
formulations is observed in the primitive head sinus (PHS), common cardinal vein (CCV), posterior cardinal vein (PCV), and caudal vein
(CV). (j) Tissue level view of liposome distribution in kdrl:GFP transgenic embryos, 1 h after injection with DOPG and DSPC liposomes at
102 hpf. Liposome accumulation is observed in the entire caudal vein (CV), but only on the dorsal side of the PCV (dPCV, arrows).
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AmBisome liposomes associated only with ECs of a subset of
blood vessels, namely the caudal vein (CV), the posterior and
common cardinal veins (PCV and CCV), and the primary head
sinus (PHS) as well as ECs within the caudal hematopoietic
tissue (CHT-ECs) (Figure 1d,f−h).31 These comprise the
majority of venous ECs within the zebraﬁsh embryo at this
developmental stage.32 Cationic EndoTAG-1 liposomes at 1
hpi associated with all ECs as expected33 but at later time
points remain associated only with venous ECs.
AmBisome, EndoTAG-1, and Myocet are each composed of
various mixtures of (phospho)lipids and cholesterol. In these
cases, lipid headgroup chemistries, fatty acid chain saturation
and cholesterol content, will together combine to aﬀect the
overall physicochemical character of the formulated liposomes
and consequently their in vivo fate. To limit potential variation
in liposome membrane composition, we next formulated and
injected ∼100 nm liposomes composed of the individual
(phospho)lipids constituting AmBisome, EndoTAG-1, and
Myocet (Figure S4 and Table S1). We also included liposomes
composed of 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycer-
ol) (DOPG) and 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC). In these experiments, injected cationic liposomes
(measured zeta potential; >30 mV) initially associated with
both arterial and venous ECs of the embryonic ﬁsh. All anionic
liposomes (<−30 mV) associated with venous ECs alone, and
the behavior of neutral liposomes was dependent on lipid fatty
acid chain saturation, whereby “ﬂuid” liposome membranes (for
example, DOPC), rich in unsaturated lipids, are freely
circulating, whereas those composed of ‘rigid’, saturated lipids
(for example, 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC)) associated with venous ECs. Of these, liposomes
composed of DSPC and DOPG associated with venous ECs of
the CCV, PHS, PCV, CHT, and CV most strongly (Figure 1i,
Figure S4a,d). Both these liposomes also accumulated in
macrophages within the CHT and along the CCV (Figure S5).
Diﬀerential distribution of nanoparticles over blood vessel
networks has previously been attributed to diﬀerences in ﬂow
patterns.7,25 However, when injections were performed in 4
Figure 2. Identiﬁcation of scavenger endothelial cells (SECs) in zebraﬁsh embryos. (a, b) Ex vivo imaging of adult Tie2:GFP transgenic mouse
organs, 1 h after injection with DOPG liposomes. (a) Liposome accumulation is observed in liver, but not in the ear skin or heart muscle. (b)
Within the liver, DOPG liposomes are observed as punctae within Tie2:GFP+ sinusoidal ECs (arrows) as well as sinusoid-associated cells
which based on shape and position were identiﬁed as KCs (arrowheads). (c) Tissue level view of lithium carmine distribution in kdrl:GFP and
mpeg:GFP transgenic zebraﬁsh embryos, 1 h after injection. Lithium carmine (carminic acid) ﬂuorescence co-localizes both with kdrl:GFP+
endothelial cells in the caudal vein and mpeg:GFP+ monocytes/macrophages (arrowheads) within the CHT. (d) Whole-embryo view of
ﬂuorescent oxLDL distribution in kdrl:GFP transgenic embryos, 1 h after injection. Accumulation of oxLDL is observed in the PHS, CCV,
PCV, and CV. (e) Whole-embryo view of ﬂuoHA distribution in kdrl:RFP transgenic embryos, 1 h after injection. Accumulation of ﬂuoHA is
observed in the PHS, CCV, PCV, and CV. (f) Tissue level view of ﬂuoHA distribution in kdrl:RFP transgenic embryos, 1 h after injection at
102 hpf. FluoHA accumulation is observed in the entire caudal vein (CV), but only on the dorsal side of the PCV (dPCV, arrows). (g) Tissue
level view of ﬂuoHA in kdrl:RFP and mpeg:RFP transgenic embryos. Co-localization of RFP expression and ﬂuoHA is observed only within
kdrl:RFP endothelial cells, but not mpeg:RFP monocytes/macrophages. (h) Tissue level view of co-injected ﬂuoHA and DOPG liposomes, 1 h
after injection reveals co-localization in SECs. Monocytes/macrophages (arrowheads) take up DOPG but not ﬂuoHA. (i) Ex vivo imaging of
adult mouse liver, 1 h after injection with ﬂuoHA and DOPG liposomes reveals widespread co-localization within sinusoidal ECs (arrows).
KCs (arrowheads) take up DOPG liposomes only.
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day-old zebraﬁsh embryos, both DOPG and DSPC liposomes
preferentially associated with only a subset of venous ECs along
the dorsal side of the PCV (dPCV) (Figure 1j). Liposome
association with a subset of ECs in a single, straight blood
vessel (where ﬂow patterns are expected to be similar
throughout) indicated dPCV ECs are a cell type distinct from
ventral PCV (vPCV) ECs. Indeed, diﬀerentiation of dPCV and
vPCV ECs has previously been observed during the induction
of lymphatic diﬀerentiation and subintestinal vein angio-
genesis,34,35 suggesting dPCV diﬀerentiation may lead to the
expression of speciﬁc receptors by these ECs which in turn
Figure 3. stab2 is required for anionic liposome uptake by SECs. (a, b) Tissue level view of DOPG (a) and DSPC (b) liposome distribution at
1 hpi in control and dextran sulfate injected embryos, with quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells
based on rhodamine ﬂuorescence intensity associated with CV vs DA. (c) stab2 domain structure predicted to be expressed from the wild-type
stab2 and the stab2ibl2 allele. (d) Whole-embryo view of f lt1:RFP, f lt4:YFP double transgenic embryos at 5 dpf to visualize blood vascular and
lymphatic development. No defects were identiﬁed during (lymph)angiogenesis and vascular patterning in stab2ibl2 homozygous embryos
compared to sibling controls. (e) Fertile adult females (stab2ibl2 homozygous and sibling controls) at 3 months post-fertilization. (f−k) Tissue
level view of ﬂuoHA (f) and DOPG (g), DSPC (h), AmBisome (i), EndoTAG-1 (j), and Myocet (k) liposome distribution at 1 hpi in stab2ibl2
and sibling control embryos, with quantiﬁcation of liposome levels associated with venous vs arterial endothelial cells based on rhodamine
ﬂuorescence intensity associated with CV vs DA. (a, b, f−k) Bar height represents median values, dots represent individual data points, and
brackets indicate signiﬁcantly diﬀerent values (*: p < 0.05, **: p < 0.01, ***: p < 0.001, N.S.: not signiﬁcant) based on Mann−Whitney test. n
= 6−10 per group (in two experiments).
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could mediate the selective binding of DOPG and DSPC
liposomes.
Identiﬁcation of a Zebraﬁsh EC Type Homologous to
Mammalian LSECs. Selective association of liposomes with
most venous ECs has not been observed in adult mammals.
However, we hypothesized a more restricted subset of ECs in
mammals could be functionally related to venous ECs of the
embryonic zebraﬁsh. To test this hypothesis, DOPG liposomes
were injected intravenously into Tie2:GFP+ adult mice. In
these mice, liposomes were removed from circulation within 1
hpi, and a striking accumulation was observed in the liver
(Figure 2a). Within the liver, liposomes associated with
Tie2:GFP+ sinusoidal ECs and with cells identiﬁed as KCs
based on cell shape and intravascular localization (Figure 2b).
No liposome accumulation was observed in hepatocytes or
other analyzed organs. This suggested venous ECs and
macrophages within the CHT and CV of the embryonic
zebraﬁsh were functionally homologous to LSECs and KCs of
the mammalian liver and comprise the RES in zebraﬁsh
embryos. To conﬁrm this, we injected colloidal lithium carmine
(Li-Car), the most prominent vital stain originally used to
deﬁne the mammalian RES, into zebraﬁsh embryos. Making use
of the inherent ﬂuorescence of carminic acid,36 we observed
accumulation of this colloid in the same blood vessels (CV,
CHT, PCV, and PHS) and subcellular structures within venous
ECs and macrophages, in which DOPG and DSPC liposomes
also accumulate (Figure 2c).
A small number of transmembrane receptors are selectively
expressed in mammalian LSECs compared to other blood
vascular ECs.11 These include the scavenger receptors Stabilin-
1 and -237 and the mannose receptor Mrc1. Analysis of the
expression patterns of their orthologs (stab1, stab2 and mrc1a)
in zebraﬁsh embryos conﬁrmed their restricted expression in
venous ECs of the PHS, PCV, CHT, and CV as described
previously.38,39 Importantly, expression of these genes becomes
enriched in the dPCV, matching observed EC binding
speciﬁcities of both DOPG and DSPC liposomes (Figure S6).
LSECs mediate the scavenging of macromolecular waste
including oxLDL and HA through receptor-mediated endocy-
tosis.40 Therefore, we injected ﬂuorescently labeled oxLDL and
HA (ﬂuoHA) and observed their rapid endocytosis, within the
same subset of venous ECs (within the PHS, CCV, (d)PCV,
and CV) (Figure 2d−f). Based on the conserved uptake of
DOPG liposome, oxLDL, ﬂuoHA, and Li-Car from circulation
and expression of known LSEC markers by this venous EC
subset in zebraﬁsh embryos, we deﬁne them as SECs -
homologous to mammalian LSECs.
In contrast to DSPC and DOPG liposomes and to oxLDL,
ﬂuoHA uptake was speciﬁc to SECs, and no uptake was
observed in macrophages (Figure 2g). We next used ﬂuoHA as
a marker for endocytosis in SECs. Co-injection of ﬂuoHA with
DSPC or DOPG liposomes resulted in precise intracellular co-
localization in all SECs of the embryonic ﬁsh, while in
macrophages only liposome internalization was observed
(Figure 2h, Figure S7). Intracellular co-localization in LSECs
(but not KCs) of ﬂuoHA and DOPG liposomes was conserved
in the adult mouse liver (Figure 2i). These results
demonstrated ﬂuoHA endocytosis is a selective vital marker
for SECs in vertebrates and oﬀered a convenient method to
study SEC diﬀerentiation in the developing zebraﬁsh embryo
(Figure S8). Importantly, we found SECs were present at the
earliest time point at which intravenous injection is possible (28
hpf). During embryonic and larval stages, SECs were
maintained within the CV, but starting at 52 hpf became
gradually restricted to the dPCV. No ﬂuoHA uptake was
observed in embryonic veins that develop during later stages,
such as in the brain and subintestinal vasculature. These results
show that SECs are one of the ﬁrst EC subtypes to emerge
during embryonic development and provide the ﬁrst analysis of
early embryonic SEC diﬀerentiation in any vertebrate.
Stabilin-2 Is Required for Uptake of Liposomes and
Other Nanoparticles by SECs. The precise intracellular co-
localization of ﬂuoHA with DOPG and DSPC liposomes in
SECs indicated the use of a shared receptor for endocytosis.
Importantly, one of the markers for SECs in zebraﬁsh embryos
and adult mammals, Stabilin-2, has been identiﬁed as the main
HA clearance receptor in the mouse liver.40 In vitro, Stabilin-2
and its paralog Stabilin-1 have been shown to bind to a large
variety of endogenous (mostly anionic) macromolecules41 as
well as phosphothiorate-modiﬁed antisense oligonucleotides
(PS-ASO),42 apoptotic cell bodies,43 biotinylated albumin,44
and carbon nanotubes.45 In vivo, Stabilin-1 and Stabilin-2 were
shown to mediate sequestration (but not uptake) by LSECs of
aged erythrocytes in a phosphatidylserine-dependent manner.46
Stabilin-1 and Stabilin-2 are both nonessential genes for
development and normal physiology in mice, with mice lacking
both Stabilin-1 and Stabilin-2 displaying deﬁcient removal of
nephrotoxic macromolecules from circulation.37 To test if
stabilins were involved in liposome uptake by SECs, embryos
were ﬁrst pretreated with dextran sulfate - a competitive
inhibitor of scavenger receptors, including stab1 and stab2.47,48
Subsequent liposome injection (or co-injection) resulted in a
striking loss of liposome uptake by SECs, oﬀset by an increase
in circulating liposomes, and particularly in the case of DOPG
liposomes, an increase in macrophage uptake (Figure 3a,b). In
contrast, injection of mannan, a competitive inhibitor of
mrc1a,49 did not inhibit liposome uptake by SECs (data not
shown).
To identify the speciﬁc role of stab1 and stab2 in liposome
uptake, mutants for both genes were generated through
CRISPR/Cas9-mediated mutagenesis. Here, we report the
analysis of a stab2 mutant line, in which we identiﬁed a 4nt
deletion (stab2ibl2), leading to a frameshift in the stab2 coding
sequence and a premature stop codon (C233X) (Figure 3c,
Figure S9). This mutation is predicted to remove most
conserved stab2 domains including all fasiclin domains, the
HA binding Link domain, and the transmembrane and
cytoplasmic segments. Homozygous stab2ibl2 mutants displayed
a strong reduction of stab2, but not of stab1 or mrc1a, mRNA
expression indicating normal SEC diﬀerentiation and nonsense-
mediated decay of stab2ibl2 mRNA (Figure S10). Stab2ibl2
mutants survived throughout embryonic development without
defects in either blood or lymphatic vascular systems, which
were described previously for stab2 morphants,50,51 and fertile
adults were identiﬁed in normal Mendelian ratios (Figure 3d,e).
Consistent with the increase in circulating HA levels observed
in mouse Stab2 knockouts,52 a complete loss of ﬂuoHA uptake
by SECs was observed in zebraﬁsh stab2ibl2 mutants, showing a
conserved role for stab2 in HA clearance in vertebrates (Figure
3f). Importantly, when either DOPG or DSPC liposomes were
injected in stab2ibl2 mutants, a strong reduction of liposome
endocytosis by SECs was observed, oﬀset by an increase in
circulating liposome levels and an increase in macrophage
uptake (Figure 3g,h). Diﬀerential liposome uptake in
neighboring venous ECs of embryos with a mosaic loss of
stab2 function indicated a cell-autonomous role of stab2
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function in liposome uptake by SECs (Figure S11). For the
original three liposome formulations screened, loss of stab2
function aﬀected AmBisome, but not Myocet or EndoTAG-1
biodistribution (Figure 3i−k). Since both AmBisome and
EndoTAG-1 accumulated within SECs of wild-type embryos,
stab2-mediated uptake by SECs appears dependent on speciﬁc
physicochemical properties of liposomes and stab2 does not
function in the clearance of cationic liposomes.
In vivo, several other scavenger receptors with similar binding
proﬁles to stab2 are expressed,11 not only on SECs but also on
other endothelial cells and macrophages. Given the signiﬁcant
increase in circulating DOPG, DSPC, and AmBisome lip-
osomes in stab2ibl2 mutants, stab2 clearly plays a dominant role
in removal of these liposomes from circulation compared to
other scavenger receptors (including the structurally related
stab1). Similarly, clearance of PS-ASOs was recently shown to
be dominated by Stab2 in the mouse liver.42 To test the
generality of stab2 function, several other polyanionic nano-
particles were injected in wild-type and stab2ibl2 mutant
embryos as well as following dextran sulfate injection (Figure
4a−l). These included endogenous (DOPS liposomes, a model
for apoptotic cell fragments), viral (Cowpea Chlorotic Mottle
Virus-like particles, CCMV VLPs),53 polymeric (polymer-
somes54 and polystyrene beads), and inorganic (quantum
dots, QDs) nanoparticles. All of these particles were
endocytosed selectively by SECs in zebraﬁsh embryos, and in
all cases SEC endocytosis could be inhibited by dextran sulfate.
However, not all nanoparticles were dependent on stab2 for
SEC endocytosis. Although uptake by SECs of DOPS
liposomes, polymersomes, and polystyrene nanoparticles was
Figure 4. stab2-mediated scavenging of anionic nanoparticles in vivo. (a−i) Tissue level view of DOPS liposome (a, b), PIB-PEG polymersome
(c, d), carboxylated polystyrene nanoparticle (e, f), CCMV virus-like particle (g, h), and carboxylated quantum dot (i, j) distribution at 1 hpi
in stab2ibl2 and sibling control embryos (a, c, e, g, i) or control and dextran sulfate injected embryos (b, d, f, h, j). Quantiﬁcation of
nanoparticle levels associated with venous vs arterial endothelial cells based on rhodamine ﬂuorescence intensity associated with caudal vein
vs DA. (a−j) Bar height represents median values, dots represent individual data points, and brackets indicate signiﬁcantly diﬀerent values (*:
p < 0.05, **: p < 0.01, ***: p < 0.001, N.S.: not signiﬁcant) based on Mann−Whitney test. n = 5−12 per group (in two experiments).
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strongly decreased in stab2ibl2 mutants, uptake of CCMV VLPs
was only partly dependent on stab2 and QD uptake appeared
stab2-independent. Alternatively, QD uptake by SECs is also
mediated in part by stab2, but its function is masked in stab2ibl2
mutants through redundancy with other scavenger receptors
(such as stab1) that can be inhibited by dextran sulfate. CCMV
VLPs (28 nm) and QDs (<10 nm) were the smallest
nanoparticles screened in this study, suggesting size may be
an important determinant of scavenger receptor−nanoparticle
interactions.
Targeted Liposomal Drug Delivery to SECs. Finally, to
demonstrate we could extend the observed interaction of
nanoparticles with SECs to cell-selective drug delivery, we
encapsulated a model drug, clodronic acid, within DSPC
liposomes (Table S2). Clodronic acid requires active transport
(endocytosis or phagocytosis) across the target cell membrane
to illicit a cytotoxic eﬀect.55 Liposome-mediated intracellular
delivery of clodronic acid into monocytes/macrophages is used
extensively as a research tool to selectively remove these cell
populations in vivo.56 After 12−24 hpi, synchronous changes in
the morphology of the CHT and caudal vein ECs were
observed, followed by a gradual loss of kdrl:GFP+ endothelial
cells or cell fragments and ultimately leading to the complete
disappearance of the caudal vein between 24 and 48 hpi (Figure
5a−d, Movie S1 and S2). The PCV and other cell types within
the CHT, including mpeg:GFP+ macrophages (most of which
are not exposed to circulating nanoparticles) as well as
mpx:GFP+ neutrophils, were largely unaﬀected (Figure S12).
Injection of free clodronic acid (a control demonstrating the
requirement of liposomal encapsulation) did not result in any
observable changes to the venous endothelium. Similarly,
injection of freely circulating DOPC-clodronic acid liposomes
(a control demonstrating the requirement of selective nano-
particle uptake by SECs) did not aﬀect the venous
Figure 5. Nanoparticle-mediated SEC deletion. (a) Whole-embryo and tissue level views at 48 hpi of the blood vasculature in kdrl:GFP
transgenic control embryos, embryos injected with 1 mg/mL clodronic acid, or embryos injected with liposomes containing 1 mg/mL
clodronic acid (DSPC or DOPC liposomes). Complete deletion of the caudal vein is observed in embryos injected with DSPC liposomes
containing clodronic acid (brackets and asterisks). (b) Schematic representation of blood ﬂow in control embryos or embryos injected with
DSPC liposomes containing 1 mg/mL clodronic acid. Blue indicates venous or capillary blood vessels, and red indicates arterial blood vessels.
Arrowheads indicate direction of blood ﬂow (based on observations from Movie S1). The removal of the CV (dashed lines) leads to a
rerouting of blood ﬂow through the DLAV. (c) Quantiﬁcation of PCV length in injected embryos. Bar height represents median values, dots
represent individual data points, and brackets indicate signiﬁcant values (**: p < 0.01, ***: p < 0.001) based on Kruskal−Wallis and Dunn’s
tests with Bonferroni correction for multiple testing. n = 6 individually injected embryos per group (in two experiments). (d) Progression of
SEC deletion. Individual frames from Movie S2 at indicated time points after injection of DSPC liposomes containing 1 mg/mL clodronic
acid, injected into kdrl:GFP transgenic embryos. SEC fragmentation in this case is observed mostly between 12 hpi and 16 hpi, followed by a
gradual loss of ﬂuorescence or removal of cellular debris. (e) Tissue level view of distribution of DSPC liposomes containing 1 mg/mL
clodronic acid at 1 hpi in stab2ibl2 and sibling control embryos. (f) Whole-embryo and tissue level views at 48 hpi of the blood vasculature in
kdrl:GFP transgenic stab2ibl2 and sibling embryos. Embryos were injected with DSPC liposomes containing 1 mg/mL clodronic acid.
Complete deletion of the caudal vein is observed in sibling control (brackets and asterisks), but not stab2ibl2 mutant embryos. (g) Schematic
representation of blood ﬂow in sibling control embryos or stab2ibl2 homozygous mutants, both injected with DSPC liposomes containing
approximately 1 mg/mL clodronic acid. Blue indicates venous or capillary blood vessels, and red indicates arterial blood vessels. Arrowheads
indicate direction of blood ﬂow (based on observations from Movie S3). The removal of the CV (dashed lines) leads to a rerouting of blood
ﬂow through the DLAV in control embryos but not in stab2ibl2 homozygous mutants. (h) Quantiﬁcation of PCV length in injected embryos.
Bar height represents median values, dots represent individual data points, and brackets indicate signiﬁcant values (***: p < 0.001) based on
Mann−Whitney test.
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endothelium. The development of the dorsal aorta was
unaﬀected by deletion of the CV and CHT, and blood supply
to the caudal parts of the embryo was maintained through a
rerouting of blood cells into the intersegmental vessels and
dorsal longitudinal anastomotic vessel (DLAV). Embryos with
a complete loss of the CV and CHT endothelial cells were agile
and could survive at least until 6 dpf. Imaging of ﬂuorescent
DSPC-clodronic acid liposomes revealed selective stab2-
dependent uptake by SECs analogous to empty DSPC
liposomes (Figure 5e). Importantly, loss of stab2 function as
observed in stab2ibl2 mutant embryos rescued the CV
phenotype induced by injection of DSPC-clodronic acid
liposomes (Figure 5 f-h, Movie S3). These results identify
stab2-mediated uptake of liposomes by SECs as a simple
strategy for intracellular compound delivery to this cell type in
zebraﬁsh embryos.
CONCLUSION
In summary, we show stab2 is an important (scavenger)
receptor mediating the uptake of circulating nanoparticles by
SECs. In particular, anionic nanoparticles, between 50 and 250
nm in size, are avidly taken up by SECs in a stab2-dependent
fashion. Here, binding and uptake appear independent of
material and functional properties of nanoparticles and are
solely dependent on surface charge. Given the comparable sizes
and surface charge of many blood-borne viruses,16−18,57
clearance of these circulating pathogens by LSECs is also
potentially mediated by stab2. These ﬁndings, combined with
the high expression of stab2 by LSECs within the mammalian
liver,11 implicate SECs as an important cell-type in the binding,
uptake, and clearance of administered nanoparticles. As such,
we support the re-adoption of the RES, over the MPS, as the
most accurate term to describe the specialized cellular
components involved in nanoparticle clearance from circu-
lation.58
The ultimate goal of many nanoparticle-based technologies is
cell-type-speciﬁc targeting. Yet reported targeting eﬃciencies
rarely surpass 1% of the total injected nanoparticle dose.1 A
major contributing factor has been oﬀ-target nanoparticle
interactions within the mammalian liver.5 By revealing the
molecular basis of nanoparticle interactions with speciﬁc cells of
the embryonic zebraﬁsh, we have been able to demonstrate
nanoparticle targeting of, and drug delivery to, speciﬁc cell
types with homologues in the mammalian liver. In addition, we
show these interactions can be eﬀectively inhibited by dextran
sulfate. As stab2 is not essential for normal adult physiology,37
this oﬀers a simple method to extend circulation lifetimes of
nanoparticles by minimizing potential oﬀ-target liver inter-
actions.59 This will likely be particularly beneﬁcial in instances
where active targeting of nanoparticles to cell types beyond the
liver (for example, cancer cells) is desired.
Importantly, the SEC/selective drug delivery we describe has
not resulted from adding further complexity to nanoparticle
designs. Instead, through systematic screening of “simple”
nanoparticles (i.e., liposomes composed of a single phospho-
lipid), we have established what general properties and
molecular mechanisms direct nanoparticles to speciﬁc cell
types. The use of the embryonic zebraﬁsh as a model organism,
and the ability to visualize nanoparticle−cell interactions at high
resolution in living organisms, has been essential in this process.
We therefore propose that the embryonic zebraﬁsh, with its
established extensive genetic toolkit, is a valuable preclinical in
vivo model allowing screening, optimization, and mechanistic
understanding of nanoparticle biodistribution, predictive of
their behavior in mammals.26
MATERIALS AND METHODS
Reagents. Fluorescein-labeled hyaluronic acid (ﬂuoHA) was
prepared through conjugation of hyaluronic acid (100 kDa) with
ﬂuorescein isothiocyanate (Isomer I, Sigma-Aldrich) as previously
described.60 Additional ﬂuoHA was provided as a kind gift from W.
Jiskoot (Leiden University, The Netherlands). Colloidal Li-Car was
prepared as previously described.61 Rhodamine-loaded polymersomes
on polyisobutadiene/polyethylene glycol (PIB/PEG) block copoly-
mers54 were a kind gift from S. Askes and S. Bonnet (Leiden
University, The Netherlands). Atto-647 labeled CCMV-virus-like
particles (t = 3, 28 nm)53 were a kind gift from M. de Ruiter and J.
Cornelissen (Twente University, The Netherlands). Purchased
reagents are described in the Supporting Information.
Liposome Preparation and Characterization. All liposomes
(without encapsulated drugs) were formulated in ddH2O at a total
lipid concentration of 1 mM. Individual lipids, as stock solutions (1−
10 mM) in chloroform, were combined at the desired molar ratios and
dried to a ﬁlm, ﬁrst under a stream of N2 and then >1h under vacuum.
With the exception of Myocet 325 and 464 nm, lipid ﬁlms were
hydrated in 1 mL ddH2O at >65 °C (with gentle vortexing if
necessary) to form large/giant multilamellar vesicles. Large unilamellar
vesicles were formed through extrusion above the Tm of all lipids (>65
°C, Mini-extruder with heating block, Avanti Polar Lipids, Alabaster,
US). Hydrated lipids were passed 11 times through 2 × 400 nm
polycarbonate (PC) membranes (Nucleopore Track-Etch membranes,
Whatman), followed by 11 times through 2 × 100 nm PC pores. All
liposomes were stored at 4 °C. With the exception of DSPC liposomes
(signiﬁcant aggregation after 1 week storage), all liposomes were stable
for at least 1 month. Myocet 325 and 464 nm liposomes were
formulated by gentle hydration of lipid ﬁlms at 35 °C (without
vortexing). In the case of 464 nm Myocet liposomes, hydrated lipids
were passed through a 800 nm PC membrane 7 times at 35 °C. In the
case of 325 nm Myocet liposomes, hydrated lipids were passed
through a 400 nm PC membrane 7 times at 35 °C. See Supporting
Information for nanoparticle characterization methods and Table S1
for all lipid compositions, size, and zeta potentials of nanoparticles
used in this study.
Clodronic Acid Encapsulation and Quantiﬁcation. Lipid ﬁlms
(10 mM total lipids) were hydrated with ddH2O containing 200
mgmL−1 clodronic acid (1 mL) and formulated through extrusion as
described for the corresponding “empty” liposomes. Unencapsulated
clodronic acid was removed by size exclusion chromatography (illustra
NAP Sephadex G-25 DNA grade premade columns (GE Healthcare)
used according to the supplier’s instructions). Eluted clodronic acid-
encapsulated liposomes were diluted 2.5× during SEC and injected
without further dilution. Quantiﬁcation of encapsulated clodronic acid
was determined by UV absorbance as previously reported.62 Brieﬂy,
liposomes were ﬁrst destroyed through a 1:1 dilution with 1% v/v
Triton X-100 solution before further dilution into an acidic CuSO4
solution (1:2.25:2.25; Liposome-Triton X-100 mix: 3 mM HNO3: 4
mM CuSO4). The concentration of clodronic acid was determined by
UV absorbance (Cary 3 Bio UV−vis spectrometer) at 240 nm and
quantiﬁed against a predetermined calibration curve (50 μM to 2.5
mM clodronic acid). All UV−vis absorbance measurements were taken
at room temperature. Blanks were made using liposome solutions
without encapsulated clodronic acid but prepared otherwise identically
(including SEC procedure). The ﬁnal encapsulated clodronic acid
concentration varied between 0.9 and 1.7 mg mL−1 (see Supporting
Information Table S2).
Zebraﬁsh Strains, in Situ Hybridization, and CRISPR/Cas9
Mutagenesis. Zebraﬁsh (Danio rerio, strain AB/TL) were maintained
and handled according to the guidelines from the Zebraﬁsh Model
Organism Database (http://zﬁn.org) and in compliance with the
directives of the local animal welfare committee of Leiden University.
Fertilization was performed by natural spawning at the beginning of
the light period, and eggs were raised at 28.5 °C in egg water (60 ug/
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mL Instant Ocean sea salts). The following previously established
zebraﬁsh lines were used Tg(kdrl:GFP)s843,63 Tg(kdrl:RFP-
CAAX)s916,38 Tg(mpeg:GFP)gl22,64 Tg(mpeg:RFP-CAAX)ump2,65 Tg-
(f lt1enh:RFP)hu5333,66 Tg(f lt4BAC:YFP)hu7135,67 and Tg(mpx:GFP)uwm1.68
Whole-mount in situ hybridization was performed as described.69
Supporting Information Table S3 lists primers for probe generation.
Cloning-free sgRNAs for CRISPR/Cas9 mutagenesis were designed
and synthesized as described.70 sgRNAs (125 pg) and cas9 mRNA
(300 pg) were co-injected into single-cell wild-type, albino or f lt4:YFP;
f lt1:RFP transgenic embryos. Mutagenesis eﬃcacy, founder identi-
ﬁcation, and genotyping were performed using CRISPR-STAT.71 The
nucleotide sequences and predicted stab2 amino acid sequences in the
stab2ibl2 line are shown in Figure S11. Table S3 lists guide RNA
sequences and genotyping primers. For mosaic analysis, heterozygous
embryos (stab2ibl/+) obtained from a cross between a stab2ibl2
homozygous parent and a kdrl:GFP (stab2+/+) parent were co-injected
with sgRNAs (125 pg) and cas9 mRNA (300 pg) to create second-hit
mutations in the wild-type allele.
Zebraﬁsh Intravenous Injections. Liposomal formulations were
injected into 2 day old zebraﬁsh embryos (52−56 hpf) using a
modiﬁed microangraphy protocol.72 Embryos were anesthetized in
0.01% tricaine and embedded in 0.4% agarose containing tricaine
before injection. To improve reproducibility of microangiography
experiments, 1 nL volumes were calibrated and injected into the sinus
venosus/duct of Cuvier. We created a small injection space by
penetrating the skin with the injection needle and gently pulling the
needle back, thereby creating a small pyramidal space in which the
liposomes and polymers were injected. Successfully injected embryos
were identiﬁed through the backward translocation of venous
erythrocytes and the absence of damage to the yolk ball, which
would reduce the amount of liposomes in circulation. For injections at
later stages (>80 hpf), 0.5 nL volumes were injected into the CCV.
The following concentrations were injected: dextran sulfate (20 mg/
mL), FluoHA (0.2 mg/mL), oxLDL (1 mg/mL), CCMV-VLP (1 mg/
mL), QDs (1:25 dilution), lithium carmine (1:50 dilution), polymer-
somes (1 mg/mL), latex beads (1:10 dilution). Dextran sulfate was
injected 20 min prior to nanoparticle injection.
Zebraﬁsh Imaging and Quantiﬁcation. For each treatment or
time point, at least six individual embryos (biological replicates) using
at minimum two independently formulated liposome preparations
were imaged using confocal microscopy. Embryos were randomly
picked from a dish of 20−60 successfully injected embryos (exclusion
criteria were: no backward translocation of erythrocytes after injection
and/or damage to the yolk ball). Confocal z-stacks were captured on a
Leica TCS SPE confocal microscope, using a 10× air objective (HCX
PL FLUOTAR) or a 40× water-immersion objective (HCX APO L).
For whole-embryo views, 3−5 overlapping z-stacks were captured to
cover the complete embryo. Laser intensity, gain, and oﬀset settings
were identical between stacks and sessions. Images were processed and
quantiﬁed using the Fiji distribution of ImageJ.73,74 Quantiﬁcation (not
blinded) of liposome biodistribution was performed on 40× confocal
z-stacks (with an optical thickness of 2 μm/slice) as described in the
Supporting Information.
Mouse Injections and Imaging. All experiments were performed
in accordance with the guidelines of the Animal Welfare Committee of
the Royal Netherlands Academy of Arts and Sciences, The
Netherlands. Tg(TIE2GFP)287Sato/J mice were sedated using
isoﬂurane inhalation anesthesia (1.5−2% isoﬂurane/O2 mixture). 100
μL of DOPG liposomes (10 mM DOPG + 1% Rhod-PE) diluted 1:5
in PBS were injected retro-orbitally with an insulin syringe (BD). After
1 h, mice were sacriﬁced, and organs were harvested and imaged ex
vivo on glass bottom dishes. Images were taken with a Leica SP8
multiphoton microscope with a chameleon Vision-S (Coherent Inc.),
equipped with four HyD detectors: HyD1 (<455 nm), HyD2 (455−
490 nm), HyD3 (500−550 nm), and HyD4 (560−650 nm). Diﬀerent
wavelengths between 700 nm and 1150 nm were used for excitation;
HA and Rhod-PE were excited with a wavelength of 960/1050 nm and
detected in HyD3 and HyD4. All images were in 12 bit and acquired
with a 25× (HCX IRAPO N.A. 0.95 WD 2.5 mm) water objective.
Statistical Analysis and Data Availability. Because of small
sample sizes, nonparametric tests were used exclusively. For
comparisons between two groups, two-tailed Mann−Whitney tests
were performed. For comparisons between multiple groups, we used
Kruskal−Wallis tests followed by two-tailed Dunn’s tests with
Bonferroni correction using the PMCMR package in R.75 No
statistical methods were used to predetermine sample size, but
group sizes were >5 in order for the null distribution of the Kruskal−
Wallis statistic to approximate the X2 distribution (with k−1 degrees of
freedom). With the exception of Figure 1e, graphs show all individual
data points and the median. Confocal image stacks (raw data) are
available from the corresponding authors upon reasonable request.
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Movie S1: An uninjected control embryo and three
DSPC-clodronic acid (10mM total lipids) liposome
injected embryos showing blood ﬂow dynamics in the
tail region and normal embryonic development 48 h after
injection. Black arrows indicate the most caudal end of
the PCV that contains bloodﬂow, and white arrows
indicate the most caudal perfused ISV (AVI)
Movie S2: Time lapse confocal imaging of a kdrl:GFP
transgenic embryo injected with DSPC-clodronic acid
(10 mM total lipids) liposome. Imaging started 6 hpi.
Confocal z-stacks were captured every 20 minutes for 24
h (AVI)
Movie S3: Three sibling control embryo and three
stab2ibl2 homozygous mutants DSPC-clodronic acid (10
mM total lipids) liposome injected embryos showing
blood ﬂow dynamics in the tail region and normal
embryonic development 48 h after injection (AVI)
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